gallery 05 · the record, by question
BPC-157 TB-500, answered from the record
Twenty-five questions about the two-peptide blend, each answered from a cited study or the audited FDA status — and each pointing to the gap where the combination data should be.
What is the Wolverine peptide blend?
A research-community name for a two-peptide pairing of BPC-157 with TB-500, discussed as a tissue-repair stack. It is not a single chemical entity or an approved product. The combination's human effect is unproven, and no controlled trial of the pairing exists [9].
What is BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid pentadecapeptide — the cytoprotective and angiogenic component. TB-500 is a synthetic Ac-LKKTETQ heptapeptide from the actin-binding region of Thymosin Beta-4 — the cytoskeletal and cell-migration component [1][3]. Two distinct peptides, paired.
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-mer gastric-juice-derived peptide acting locally via VEGFR2 and eNOS; TB-500 is a 7-mer fragment of Thymosin Beta-4 acting via G-actin sequestration [2][3]. Different size (~1419.5 Da versus ~889 Da), different origin, different mechanism, paired for complementary effects.
What is the BPC-157 and TB-500 blend used for in research?
It is studied in preclinical, mostly rodent, tissue-repair models: BPC-157 in tendon, ligament, and wound work [1]; TB-500 / Thymosin Beta-4 in cell migration, re-epithelialization, and angiogenesis [4]. No human combination efficacy is established [9].
Why are BPC-157 and TB-500 combined (the Wolverine stack)?
The rationale pairs BPC-157's local cytoprotective and pro-angiogenic signal with TB-500's actin-sequestration and cell-migration signal as complementary mechanisms [2][3]. This synergy is a theoretical extrapolation, not a finding from any controlled combination study.
Is there any study showing BPC-157 and TB-500 work better together (synergy)?
No. A 2025 systematic review of BPC-157 — 36 studies, only one human — makes no mention of TB-500 or combination use, and no peer-reviewed study defines a synergy ratio, dose, or endpoint for the two given together [9].
Are there human clinical trials on the BPC-157 + TB-500 combination?
There are no controlled clinical trials of the combination. Human data exist only for the individual constituents and are thin: three small BPC-157 pilots, and human data labeled "TB-500" are for full-length Thymosin Beta-4, not the heptapeptide [6][7][9].
Does the BPC-157 TB-500 blend help tendon and ligament injuries?
In animal models, BPC-157 accelerated healing of a transected rat Achilles tendon across biomechanical, functional, and microscopic measures [1]. These are preclinical, single-compound findings; the blend's effect in humans is unproven [9].
Does BPC-157 and TB-500 help muscle tears and recovery?
Recovery interest rests on preclinical work — BPC-157 tendon and tissue studies [1] and Thymosin Beta-4 cell-migration findings [4]. No controlled human study supports muscle-recovery claims for the blend [10].
How does TB-500 work (actin / Thymosin Beta-4)?
TB-500's LKKTETQ motif binds monomeric G-actin one-to-one. Crystallography of a Thymosin Beta-4-actin complex showed it sequesters the monomer by capping both ends, regulating the cytoskeletal dynamics that drive cell migration [3].
How does BPC-157 work compared to TB-500?
BPC-157 acts through a local cytoprotective and pro-angiogenic route — VEGFR2-Akt-eNOS up-regulation [2]. TB-500 acts through intracellular actin sequestration governing cell migration [3]. The two are described as complementary but largely non-overlapping.
Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?
BPC-157 is pro-angiogenic via VEGFR2 up-regulation and internalization with downstream VEGFR2-Akt-eNOS signaling; TB-500 / Thymosin Beta-4 promotes angiogenesis through endothelial migration [2][4]. Both are reported in animal and in-vitro models.
What is the half-life of BPC-157 and TB-500?
A rat-and-dog pharmacokinetic study reported BPC-157's elimination half-life as under 30 minutes [5]. No validated human half-life exists for either constituent at research doses, and none for the blend [6][7].
How do you reconstitute a BPC-157 / TB-500 blend (10mg)?
Both are supplied as lyophilized powders reconstituted in bacteriostatic or sterile water and refrigerated for research handling. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed [8].
How often should you inject BPC-157 and TB-500?
There is no validated dosing schedule for the blend; community "loading then maintenance" protocols have no controlled-trial basis [9]. The underlying animal studies used per-body-weight doses that are not human guidance [1].
How much BPC-157 and TB-500 should be used per week?
No validated blend dose exists. Commercial vials commonly pair fixed combined masses (for example ~10 mg plus ~10 mg), but no peer-reviewed combination dose-finding study supports any weekly amount [9].
Can BPC-157 and TB-500 be taken orally instead of injected?
BPC-157 is studied as a "stable gastric" peptide and oral blend products are marketed, but those products lack validated pharmacokinetics [5]. Subcutaneous and intramuscular are the predominant research-community routes.
Can you mix BPC-157 with TB-500 in the same syringe?
A common community practice is to reconstitute the two peptides separately or in a shared vial. There is no controlled study defining a combined formulation, and unregulated material has unverified ratio and purity [8].
How do you cycle BPC-157 and TB-500?
Community "loading then maintenance" cycling protocols have no controlled-trial basis. No validated blend schedule exists; described findings are preclinical and dosed per body weight in animals [9].
What are the side effects of BPC-157 and TB-500?
Human safety data are limited to the individual constituents — full-length Thymosin Beta-4 was well tolerated in intravenous Phase 1 studies [6][7]. The blend's combination safety is unproven, and reviews note potential for serious harm with unapproved peptides [10].
Does TB-500 cause cancer or promote tumor growth?
Thymosin Beta-4 is implicated in tumor metastasis and angiogenesis; the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression [4]. This is a safety consideration, not a demonstrated outcome in blend users.
Are BPC-157 and TB-500 FDA approved or banned by WADA?
Neither has FDA authorization for human use, and the blend has no authorized indication; FDA's page, current as of April 22, 2026, no longer carries either ingredient in Category 2 and displays both under "Bulk drug substances nominated but withdrawn" [12]. Both are also prohibited by WADA — BPC-157 under S0 non-approved substances, TB-500 / thymosin beta-4 under prohibited peptide and growth-factor categories. The audited detail is on the legal-status page [13][14].
Is Wolverine (BPC-157 + TB-500) legal?
Neither constituent has FDA authorization as a drug, and the blend has no authorized indication; FDA's current table shows that both nominations were withdrawn and omits both components from Category 2 [12]. The audited FDA 503A and WADA detail is on the legal-status page [13][14].
Can you get BPC-157 from a compounding pharmacy?
FDA placed BPC-157 in Category 2 with the September 29, 2023 list update; its current page instead records that the nomination was withdrawn and no longer includes the peptide in Category 2, but FDA has not explained what that record means for pharmacy access [12][13]. The audited regulatory detail is on the legal-status page.
What is the FDA 503A status of Wolverine?
Both constituents are unapproved for human use; FDA's September 29, 2023 update placed them in Category 2, but their nominations were later withdrawn and the current table omits both from that category [12]. FDA's staff proposed against listing both before the July 23-24, 2026 advisory-committee meeting, and FDA has published no record of the committee's votes as of September 17, 2026 [14]. See the audited detail on the legal-status page.